Innovating cancer diagnostics

Southampton Science Park is delighted to welcome CanSense Ltd, one of ten high potential start-ups given a place on the Park’s sought-after Catalyst business accelerator. 

CanSense is developing an alternative way to detect bowel cancer at an early stage. Its blood-based solution is accurate, non-invasive and inexpensive and so will be of benefit to public and private healthcare providers and pharmaceutical companies around the world.

Early diagnosis is a significant factor in reducing mortality rates – important because bowel (colorectal) cancer is the leading cause of cancer-related death in the western world. Globally, it is the second most common cancer with 450,000 new cases per year.

The company’s founder Adam Bryant has developed the technology to post-clinical pilot stage.  He commented: “CanSense is now at a point where securing funding with partners that understand the business and the marketplace in such a way that they can become strategic associates on our journey, is vital. I was pleased to be accepted onto the Catalyst programme which will not only connect me with trusted advisors but also, I hope, pave the way towards securing this funding.”